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Abstract 
Background: Adeno-associated virus (AAV) gene therapy vectors have shown the best outcomes in human clini-
cal studies for the treatment of genetic diseases such as hemophilia. However, these pivotal investigations have also 
identified several challenges. For example, high vector doses are often used for hepatic gene transfer, and cytotoxic T 
lymphocyte responses against viral capsid may occur. Therefore, achieving therapy at reduced vector doses and other 
strategies to reduce capsid antigen presentation are desirable.
Methods: We tested several engineered AAV capsids for factor IX (FIX) expression for the treatment of hemophilia B 
by hepatic gene transfer. These capsids lack potential phosphorylation or ubiquitination sites, or had been generated 
through molecular evolution.
Results: AAV2 capsids lacking either a single lysine residue or 3 tyrosine residues directed substantially higher coagu-
lation FIX expression in mice compared to wild-type sequence or other mutations. In hemophilia B dogs, however, 
expression from the tyrosine-mutant vector was merely comparable to historical data on AAV2. Evolved AAV2-LiC 
capsid was highly efficient in hemophilia B mice but lacked efficacy in a hemophilia B dog.
Conclusions: Several alternative strategies for capsid modification improve the in vivo performance of AAV vectors in 
hepatic gene transfer for correction of hemophilia. However, capsid optimization solely in mouse liver may not predict 
efficacy in other species and thus is of limited translational utility.
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Background
Adeno-associated viral (AAV) vectors represent some 
of the most powerful tools for in vivo gene transfer to a 
variety of organs. For example, impressive successes with 
ocular gene transfer have been reported, resulting in 
reversal of inherited forms of blindness [1]. AAV vectors 
have also been in clinical development for hepatic gene 
transfer over the past decade, primarily to express coag-
ulation factors in hepatocytes for the treatment of the 
X-linked bleeding disorder hemophilia. Most recently, 
curative levels of factor VIII (FVIII) and factor IX (FIX) 
were achieved in patients with hemophilia A or hemo-
philia B, respectively [2, 3]. This was achieved using viral 
capsids derived from several different serotypes. How-
ever, in some cases very large vector doses were required. 
The viral capsid is a major determinant of AAV tropism, 
and some capsids have not performed as efficiently in 
humans as they did in preclinical studies. In particular, 
transduction of mouse liver has been more effective than 
human liver. Thus, the search for optimal serotypes/cap-
sids for transduction of human hepatocytes continues, 
for instance through studies in non-human primates or 
in “humanized” mice with chimeric mouse–human liv-
ers [4, 5]. Another obstacle that continues to negatively 
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capsid-specific  CD8+ T cells [6]. Hepatocytes cross-pre-
sent the viral input capsid antigen via MHC I, following 
endosomal escape of the infecting viral particles, ubiquit-
ination, and proteasomal degradation [7–9]. Capsid-spe-
cific cytotoxic T lymphocytes can target AAV transduced 
hepatocytes, resulting in loss of expression and toxicity 
[10, 11]. Immune suppression regimens have been devel-
oped to counter these T cell responses [12, 13].
Enhancing the performance of AAV gene transfer 
could potentially result in therapy at lower vector doses, 
which should also reduce capsid antigen presentation. It 
is hoped that reducing capsid antigen below a threshold 
level will resolve this issue. We sought to develop vectors 
that are effective at lower vector doses and postulated 
that AAV capsids could be engineered to alter intracel-
lular trafficking post-entry of the vector into target cells, 
thereby enhancing delivery to the nucleus. Our studies 
of the life cycle of AAV2 demonstrated that shunting of 
viral particles to the proteasome and subsequent degra-
dation is promoted by phosphorylation of capsid tyrosine 
(Y) residues, which provide a signal for capsid polyubiq-
uitination [14]. Therefore, we hypothesized that substitu-
tion of surfaced exposed tyrosine residues in the AAV2 
capsid would significantly reduce proteasomal process-
ing of capsid. Thus, we individually mutated seven sur-
face exposed tyrosine residues at positions (252, 272, 444, 
500, 700, 704, and 730) to phenylalanine and observed 
enhanced in vitro transduction at residues 444, 500, and 
730, that was not augmented by either tyrosine kinase or 
proteasome inhibition. These mutant capsids showed a 
reduction in polyubiquitination and directed increased 
trafficking to the nucleus [15]. The combination of Y444F, 
Y500F, and Y730F mutations (AAV2-(Y-F)-M3) resulted 
in the best improvement in vitro, and in vivo for murine 
hepatocyte transduction [16]. As immunological presen-
tation of capsid antigen is dependent on proteasome deg-
radation, the M3 mutation protected AAV transduced 
human hepatocytes in  vitro and murine hepatocytes 
in vivo from  CD8+ T cell targeting and killing, thus vali-
dating our hypothesis [9].
Besides surface-exposed tyrosine residues, serine and 
threonine residues represent potential phosphorylation 
sites on the AAV capsid. Elimination of lysine residues 
may directly prevent ubiquitination, as opposed to the 
indirect method of preventing capsid phosphorylation, 
which serves as a signal for ubiquitination [17]. After 
identifying an optimal combination of Y-F variants for 
hepatocyte gene transfer, we therefore sought to deter-
mine if substitution of alternative kinase targets serine (S) 
and threonine (T) and ubiquitin target lysine (K) would 
further improve transduction [18, 19]. In an alternative 
strategy, we developed a combinatorial library, initially 
based on the AAV2 cap sequence, with an unprecedented 
complexity to select for capsid variants that optimally 
infect hepatocytes [20, 21]. As proof-of-principle, we 
selected for two variants, termed AAV2-LiA and AAV2-
LiC, with high tropism for murine liver [20]. Here, we 
evaluated AAV2-LiA and AAV2-LiC variants for cor-
rection of murine hemophilia B by hepatic gene trans-
fer. Further we compared several engineered AAV2 and 
AAV8 capsid variants with Y, S, T, and L substitutions for 
in  vivo F9 gene transfer to mouse liver. Finally, AAV2-
(Y-F)-M3 and AAV2-LiC were tested in a large animal 
model, hemophilia B dogs, for FIX expression following 
liver-directed gene transfer.
Methods
AAV vector construction and production
Site-directed mutagenesis and plasmids pACGr2c2 and 
pACGr2c8 was performed as previously described using 
a two-stage PCR reaction [15, 18, 19]. AAV2-LiA and 
AAV2-LiC were identified by sequencing DNA isolated 
from liver tissue following three successive rounds of 
in  vivo capsid library infection as previously described 
by Marsic et al. [20]. AAV vectors expressing human F9 
from the liver-specific ApoE enhancer and α1-antitrypsin 
promoter were packaged into AAV2, AAV2-LiA, AAV2-
LiC, AAV2 variants (Table 1), AAV8, and AAV8 variants 
(Table 1) capsids as previously published [16].
Experimental animals
Murine studies were approved under University of Flor-
ida Institutional Animal Care and Use Committee pro-
tocol #201503182. Male hemophilia B mice on a BALB/c 
background (BALB/c-F9−/Y) are bred onsite and have 
a targeted deletion of the murine F9 gene [22, 23]. Male 
C57BL/6 mice were purchased from The Jackson Labo-
ratory (Bel Harbor, ME). All studies were conducted in 
mice 6–8  weeks old. Vector was infused by tail injec-
tion at either 1 × 1010 or 1 × 1011 vg as indicated. When 
indicated, BALB/c-F9−/Y mice received a subcutaneous 
immunization of 1 IU recombinant FIX protein in adju-
vant (Sigma Adjuvant System S6322). Blood samples for 
BALB/c-F9−/Y mice were collected by tail transection 
into 3.8% citrate buffer (0.38% final). For all C57BL/6 
studies mice were bled from the retro-orbital plexus into 
heparinized micro-capillary tubes.
A canine hemophilia B dog colony is maintained at the 
Francis Owen Blood Research Laboratory (University of 
North Carolina at Chapel Hill). These animals have a mis-
sense mutation (E379G) in canine factor IX that results 
in misfolded cFIX protein and complete absence of cFIX 
protein in circulation. All experiments were conducted 
in male hemophilia B dogs that were pre-screened for 
anti-AAV neutralizing antibodies prior to enrollment. All 
animals were housed in US Department of Agriculture 
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approved facilities and the experimental protocol was 
approved by the Institutional Animal Care and Use Com-
mittee at UNC-Chapel Hill. The weights and ages of ani-
mals at the time of vector infusion are listed in Table  2. 
Plasma was collected per study protocol and shipped to 
UF. CBC, WBCT, and other routine blood tests were per-
formed onsite at UNC-Chapel Hill on a scil Vet abc cell 
counter calibrated for canine cells. Vector was infused by 
portal vein (AAV2-(Y-F)-M3) and saphenous vein (AAV2-
LiC) at the indicated vector doses as published [24].
Blood/plasma analysis or FIX, coagulation, and antibody 
assays
Plasma samples from hemophilia B mice and dogs were 
analyzed using a modified activated partial thrombo-
plastin time assay (aPTT). The %hFIX activity in mice 
or %cFIX activity in dogs was determined from a log–
log standard curve generated from dilutions of normal 
human and dog plasma. Inhibitory antibodies to hFIX 
or cFIX were measured by Bethesda assay as previously 
described [25, 26]. One Bethesda unit is defined as the 
reciprocal of the dilution of test plasma at which 50% of 
cFIX or hFIX activity is inhibited. Measurements were 
carried out on a Diagnostica Stago STart Hemostasis 
Analyzer (Parsippany, NJ). Levels of hFIX antigen in mice 
and IgG1 antibodies to FIX were measured by enzyme-
linked immunosorbent assay (ELISA) as previously 
described [25]. Levels of cFIX antigen in mouse plasma 
were measured by ELISA (Affinity Biologicals CFIX-EIA) 
using a standard derived from normal pooled canine 
plasma following the manufacturer’s protocol.
Detection of AAV NAB
Neutralizing antibodies (NABs) against AAV2(Y-F)-M3 
or AAV2-LiC vector particles were measured by inhi-
bition of in  vitro GFP transduction of HeLa cells and 
reported as the reciprocal dilution of plasma that resulted 
in 50% inhibition of transduction relative to control cells 
transduced with virus alone. Cells were co-infected with 
adenovirus to enhance AAV mediated GFP expression.
Statistical analysis
Results are presented as mean ± SD. Differences between 
experimental groups were evaluated using one-way 
ANOVA with Turkey multiple comparisons test or 
unpaired T tests when only two groups were compared.
Results
Lysine mutant capsid as potential alternative to tyrosine 
mutations for improved factor IX expression
Previous reports have shown that elimination of sur-
face exposed lysine residues, a putative site for poly-
ubiquitination, on AAV2 leads to an increase in murine 
hepatocyte transduction efficiency over wild-type capsid 
[19, 27]. Yet a limitation of these studies was the use of a 
non-secreted transgene product, GFP or luciferase, that 
hindered quantitative comparison of transgene expres-
sion and did not account for systemic delivery as needed 
in the treatment of hemophilia. Secondly, some of these 
studies were conducted in reference to wild-type AAV2 
and lack direct comparison to the optimized AAV2(Y-
F)-M3 capsid [16]. In the present study, we evaluate the 
efficacy of two single (K-E) substitutions at positions 
Table 1 Summary of AAV variants and mouse strains tested
Serotype (Y-F) (T-V) (K-E) Mouse
AAV2-(Y-F)-M3 444, 500, 730 C57BL/6
AAV2-(Y-F)-M3-T491V 444, 500, 730 491 C57BL/6
AAV2-(Y-F)-M3-(T491+550V) 444, 500, 730 491 and 550 C57BL/6
AAV2-K544E 544 C57BL/6
AAV2-K556E 556 C57BL/6




AAV8-(Y275+447+733F) 275, 447, and 733 C57BL/6
Table 2 Overview of hemophilia B canine studies
Dog Serotype Route Dose (vg/kg) Weight (kg) Age (year month) Gender
O19 AAV2(Y-F)-M3 PV 2 × 1011 27.8 2 year 1 month Male
O58 AAV2(Y-F)-M3 PV 6 × 1011 23.2 2 year 6 month Male
Bruce AAV2-LiC IV 6 × 1011 21.4 4 year 1 month Male
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544 or 556 compared against both AAV2 and AAV2(Y-
F)-M3 vectors in C57BL/6 mice using a ssAAV-ApoE-
hAAT-hF9 vector (expression from the ApoE hepatocyte 
control region and enhancer, combined with human α1-
antitrypsin promoter) that expresses human factor IX 
protein (hFIX) from a liver specific promoter summa-
rized in Table 1. Although a K to R substitution conserves 
the amino acid charge, in our hands we were unable to 
generate suitably infectious viral particles [19, 27].
Mice were injected in the tail vein with 1 × 1010 vg of 
each vector, and hFIX levels were determined in plasma 
by ELISA at 1  month after gene transfer. On average, 
AAV2-K544E yielded a 3.6-fold increase in systemic hFIX 
expression compared to AAV2, although not reaching 
a statistically significant difference. In contrast, AAV2-
K556E treated mice had a significant and more robust 
increase in levels of circulating hFIX protein compared to 
AAV2 (13.5-fold, Fig. 1a). These did not quite reach the 
levels of AAV2(Y-F)-M3 treated mice, which expressed 
2.3-fold higher hFIX as compared to AAV2-K556E trans-
duced mice. Hence, K556 may be a critical site for AAV2 
capsid ubiquitination, and elimination of this single lysine 
residue increases transgene expression to near the levels 
achieved with optimal multiple tyrosine mutant capsid.
Next, we asked if a single (T491V) or double (T491V 
and T550V) threonine mutants combined with AAV2-
(Y-F)-M3 would further enhance murine hepatocyte 
gene transfer, as has been suggested in prior work [18]. In 
contrast to those earlier data obtained with non-secreted 
reporter genes, we did not observe an improvement 
in hFIX levels with the addition of either T mutation 
(Fig. 1a). AAV2-(Y-F)-M3 injected mice expressed 31.5-
fold more hFIX compared to wild-type AAV2, consistent 
with our previously published findings (Fig. 1a) [16].
Inability to further improve AAV8 performance in murine 
liver
Among naturally occurring serotypes, AAV8 has the 
highest transduction efficiency of murine liver. We have 
recently shown that substitution of surface exposed 
lysine (K) residues in AAV8 did not lead to a substantial 
improvement in murine liver transduction and in some 
instances, was detrimental [19]. Therefore, we tested if 
instead, substitution of surfaced exposed tyrosine (Y) 
Fig. 1 In vivo evaluation of murine liver gene transfer in wild-type AAV2 and AAV8 vectors and respective variants. Male C57BL/6 mice (n = 4 per 
group) were injected by tail vein with 1 × 1010 vg of an AAV vector (ApoE-hAAT-hF9) expressing human FIX protein from a liver specific promoter. 
hFIX levels in plasma was determined by ELISA at 4 weeks following vector injection for a AAV2 and variants with b statistical summary and c AAV8 
and variants with d statistical summary. The specific Y, T, and K mutations of each capsid are summarized in Table 1. Relative fold difference between 
groups is listed above selected groups and the amount of “*” included is as reported by one-way ANOVA Tukey multiple comparisons test
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or threonine (T) residues could further improve hepatic 
AAV8 gene transfer in mice. AAV2 and AAV8 amino acid 
alignment and surface residue prediction resulted in the 
identification of AAV8 Y residues 275, 447, and 733 and 
a T residue at position 494, which maps closely to those 
identified in AAV2, excluding Y-275. However, neither 
AAV8(Y-F)-M3 nor AAV8-T494V vectors improved 
hFIX expression levels compared to wild-type AAV8 
(Fig.  1b), similar to our previous findings with lysine 
substitutions.
Partial correction of canine hemophilia B 
with AAV2-(Y-F)-M3 vector
An advantage in development of novel therapies for 
hemophilia is the existence of a well characterized large 
animal model, in form for hemophilic dogs [28, 29]. Of 
the various Y, K, S, and T mutation capsids, AAV2-(Y-F)-
M3 showed the strongest improvement in hFIX expres-
sion in mouse liver compared to the parent capsid, in 
this case AAV2. Previously, several hemophilia B dogs 
injected in the mesenteric or portal vein with an AAV2-
(ApoE)4-hAAT-cF9 vector, expressing canine FIX (cFIX), 
at doses of approximately 1 ×  1012  vg/kg achieved sus-
tained therapeutic levels of  ~5% of normal for multiple 
years [30, 31]. Based on these studies, we elected to test 
AAV2-(Y-F)-M3 in the canine model. We constructed a 
vector that expresses cFIX from the ApoE/hAAT combi-
nation used in the mouse experiments described above 
(thus similar to the hAAT promoter combined with 4 
copies of the ApoE enhancer in the previously published 
studies). The vector was to be administered to male 
hemophilia B dogs from the UNC-Chapel Hill colony. 
These dogs have a missense mutation, leading to expres-
sion of cFIX in hepatocytes but lacking circulating cFIX 
antigen and activity [32]. All prospective subjects were 
screened for lack of AAV capsid neutralizing antibod-
ies using an in  vitro neutralizing antibody (NAB) assay. 
Since in mice we observed a significant enhancement in 
hFIX expression following portal vein delivery of AAV(Y-
F) mutant vector compared to peripheral vein injection 
[15], we chose to administer the AAV2-(Y-F)-M3 vector 
via the portal vein.
Two male dogs O19 2.1 years and O58 2.5 years were 
chosen, see Table 2 for details. The first animal, O19, was 
injected at a vector dose of 2 × 1011 vg/kg, approximately 
fivefold lower than historically treated AAV2 dogs, into 
the portal vein [24]. To cover the animal during the sur-
gical intervention, O19 received coverage with normal 
dog plasma with a total of 450 mL on the day of injection 
followed by 300 mL on days 1, 2, and 3 post-injection. A 
hematoma was noted at the injection site on day 15 post-
injection, and 150 mL plasma was administered on days 
15, 16, 17, and 18. As a result of gene transfer, WBCT 
fell from pre-treatment of greater than 60 min to a mean 
of 21.8 ± 2.2 min (calculated from day 29 onward) post 
gene therapy (Fig. 2a, blue tracing). Canine FIX activity, 
measured over a period of 97 days post treatment, ranged 
from 0.3 to 1.5% of normal. At study endpoint, cFIX 
activity was approximately 0.5% of normal (Fig. 2b, blue 
tracing). Clinical chemistry and CBC revealed a moder-
ate reduction in platelet counts over the course of the 
study and a mild to moderate elevation in ALT prior to 
treatment and towards the end of the study on days 97, 
140, and 175 (Additional file 1: Table S1).
A second animal, O58, was injected with a threefold 
higher vector dose of 6 ×  1011  vg/kg and was followed 
over time. Dog O58 received 800 mL normal plasma over 
the course of the day of injection, followed by 350  mL 
on day 1, 400  mL  day 2, and 200  mL on days 3, 4, and 
5. There were no major complications or bleeds follow-
ing vector injection. Clinical chemistry and CBC counts 
revealed a mild reduction in platelets and a slight eleva-
tion in hematocrit and hemoglobin (Additional file  2: 
Table S2). At this higher vector dose, WBCTs decreased 
from a pre-treatment value of 48  min to an average of 
19.1 ±  2.6  min (Fig.  2a, red tracing). A cFIX activity of 
around 1% of normal was achieved (Fig. 2b, red tracing), 
when the WBCT was 14-18 min. As expected for hepatic 
gene transfer to these animals with a F9 missense muta-
tion, gene transfer did not induce an inhibitor against 
cFIX in either dog (Additional file 3: Figure S1).
Treatment of murine and canine hemophilia B using 
capsids evolved to optimally transduce murine liver
Next, we investigated the efficacy of two AAV2 vari-
ants that were selected for murine hepatocyte tropism 
through repetitive rounds of screening a rationally 
designed capsid library [20]. AAV2-LiA contains two 
Y-F substitutions at 444 and 500 in addition to 12 addi-
tional mutations, while AAV2-LiC has only a single Y-F 
substitution at position 500 and 3 additional mutations 
(Table  1) [20]. Unlike AAV2-(Y-F)-M3, both AAV2-LiA 
and AAV2-LiC serotyped vectors are equivalent to AAV8 
for hFIX expression in mouse liver, providing compara-
ble levels following intravenous delivery. Therefore, we 
tested the efficacy of both AAV2-LiA and AAV2-LiC in 
hemophilia B mice (BALB/c-F9−/Y) injected at a dose of 
1  ×  1011  vg with ssAAV-ApoE-hAAT-hF9 vector. Mice 
were followed over time for hFIX protein levels by ELISA, 
and activity levels were derived from a standard curve in 
an aPTT assay. Mice treated with either vector expressed 
comparable levels of hFIX protein and had similar high 
activity, which reached normal to super physiological 
levels of up to  ~150% (Fig.  3a, b). Nine weeks follow-
ing vector injection, vector treated and naïve mice were 
immunologically challenged with 1  IU of recombinant 
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hFIX protein in adjuvant. None of the animals treated 
with gene therapy developed antibodies against hFIX or 
had a reduction in circulating hFIX protein or coagula-
tion activity (Fig.  3a–c), while naïve challenged BALB/
c-F9−/Y mice developed robust anti-FIX titers. Thus, 
hepatic gene transfer had induced humoral tolerance to 
hFIX.
To test one of these capsids, which were highly effi-
cient in hemophilic mice, in the hemophilia B dog 
model, we produced AAV2-LiC-ApoE-hAAT-cF9 vec-
tor. We confirmed in mice that the vector directed high 
levels of cFIX expression (~30-fold higher compared to 
the AAV2-(Y-F)-M3 vector when normalized to vector 
dose, Fig. 4a). Three prospective animals were screened 
for the presence of pre-existing NAB against AAV2-LiC, 
and all three were negative. Based on previous outcomes 
with AAV8 vectors in hemophilia B dogs [33], and com-
parable gene transfer efficiency of AAV2-LiC with AAV8 
in mice [20], we selected a vector dose of 6 × 1011 vg/
kg with intravenous delivery into our subject (hemo-
philia B dog Bruce, 4.1 years, Table 2). Clinical chemis-
try and CBCs did not reveal any abnormalities over the 
course of the study, results are presented in Additional 
file  4: Table S3. However, Bruce achieved only a mod-
est decrease in WBCT from  >60  min to an average of 
34.4 ± 3.8 min (Fig. 4b), without evidence for inhibitor 
formation (Additional file  3: Figure S1). As expected 
from the WBCTs, cFIX activity was consistently <0.5% 
of normal (Fig.  4c). Thus, the high efficiency of FIX 
expression in hepatic gene transfer from peripheral vein 
in mice did not translate into efficacy in hemophilic 
dogs.
Discussion
Current gene therapy trials for the treatment of hemo-
philia A and B are all based on liver-directed gene trans-
fer with AAV vectors injected into a peripheral vein [2, 
3]. Different serotypes with liver tropism are used to 
transduce hepatocytes. Major advantages of liver gene 
transfer include the capacity of hepatocytes to efficiently 
secrete proteins into the circulation, their ability to per-
form the posttranslational modifications that are needed 
to produce biologically active FVIII and FIX, and induc-
tion of immune tolerance to the hepatocyte-expressed 
transgene product [34]. Current obstacles are the high 
vector doses that are typically required and activation of 
capsid-specific  CD8+ T cells. Both problems can poten-
tially be addressed by engineering the capsid. Informed 
by an improved understanding of the biology of the viral 
interactions with target cells, specific mutations can be 
designed to eliminate amino acids that promote protea-
somal degradation of capsid, thereby limiting efficacy and 
increasing MHC I antigen presentation [17].
Empirical evaluation of candidate mutations reveals 
alternative classes of amino acid changes that improve 
performance of different serotype capsids
With the goal of eliminating either capsid phosphoryla-
tion or ubiquitination, we tested a variety of amino acid 
changes. Combinations of these may have synergistic 
effects. As of now, there is no method to predict their 
effects. Thus, these candidate mutations have to be 
empirically evaluated. Our initial focus was on Y-F muta-
tions, which were most optimal for AAV2 in a combina-
tion of 3 specific capsid residues. In the case of AAV3, a 
Fig. 2 Hemophilia B dogs injected with two different doses of AAV2-(Y-F)-M3-ApoE-hAAT-cF9 vector do not express therapeutic levels of cFIX 
protein. a Whole blood clotting times (WBTC) and b cFIX activity of dogs O19 (blue 2 × 1011 vg/kg) and O58 (red 6 × 1011 vg/kg) over time. Colored 
arrows indicate infusion of wild-type dog plasma. Normal WBCT is indicated by shaded gray area on graph
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serotype that infects human and primate hepatocytes but 
is ineffective for mouse, Y-F mutations only have a mod-
est effect, while a combination of S-V and T-V mutations 
is more optimal [4, 35–37]. Recently, we began to evalu-
ate K-E mutations [19]. Consistent with our published 
findings using reporter genes, K556E mutation substan-
tially improved FIX expression from an AAV2 vector 
in hepatic gene transfer. Although not quite as effective 
as the optimal Y-F triple mutation, it is remarkable that 
elimination of a single lysine residue can improve efficacy 
by ~1 log (Figs. 1a, 4a). Unfortunately, it does not appear 
that this mutation can be combined with others with-
out losing vector yields or infectivity, as changes in cap-
sid structure may impact assembly [19]. More research 
is required to test whether the K556E mutation indeed 
reduces AAV2 capsid ubiquitination and to determine 
the effect on MHC I presentation of capsid antigen.
Previously, we found that the addition of T491V to 
Y444,500,730F further improved transduction and 
transgene expression. However, the effect was more mod-
est than the improvement observed for Y444,500,730F 
compared to single Y-F mutations. Compared to wild-type 
AAV2, most of the increase in efficacy can be attributed 
to the Y730F mutation. With each further optimization, 
improvement becomes more incremental. Although addi-
tion of T491V may somewhat further increase transloca-
tion of Y444,500,730F vector to the nucleus, this results 
in no further improvement in systemic FIX expression. 
The exact mechanism of enhanced gene transfer by spe-
cific combination of mutations is unknown. One poten-
tial explanation for the improvement in gene transfer with 
(Y444,500,730F) over the individual Y-F mutations is that 
the respective localization of these three residues may reg-
ulate ubiquitination based on integrative signaling [38].
Engineering fails to improve the gold standard for mice, 
AAV8
Next we investigated if engineering could improve 
murine hepatocyte transduction efficiency of AAV8. 
Using synonymous Y and T residues in AAV8 we gener-
ated two AAV8 variants AAV8-(Y-F)-M3 (275, 447, 733) 
and AAV8-T494V, which closely mimic previous AAV2 
variants. As seen with AAV8K variants [19], both vari-
ants failed to improve hFIX expression over wild-type 
AAV8. AAV8 serotype vectors have exceptional natu-
ral tropism for murine hepatocytes in  vivo [39]. Unlike 
AAV2, transduction efficiency is independent of delivery 
route [40], and upon cellular entry AAV8 viral particles 
Fig. 3 AAV2-LiC capsid selected for murine hepatocyte tropism normalizes coagulation and induces tolerance in hemophilia B mice. Hemophilia B 
mice (BALB/c-F9−/Y) were intravenously injected with 1 × 1011 vg of either AAV2-LiA or AAV2-LiC ApoE-hAAT-hF9 vector and followed over time for 
a hFIX protein levels b % FIX coagulation activity, and c anti-hFIX IgG1 antibody titers. Horizontal dotted line in a–c denotes time of adjuvant-hFIX 
challenge in mice
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rapidly release their genetic cargo [39]. In contrast, even 
though AAV2 serotype vectors have been shown to infect 
nearly all murine hepatocytes, transgene expression is 
often restricted to a small fraction of hepatocytes [41]. 
We have shown that this is mediated in part by phos-
phorylation of the FKBP52 protein and suppression of 
second-strand synthesis [42, 43]. The kinetics of AAV8 
vector uncoating, second strand synthesis, and transgene 
expression may explain how ssAAV8 vectors bypass this 
suppression. Our collective data suggest that in mice the 
ubiquitination-proteasome pathway is not rate limiting 
for AAV8 gene transfer in mouse liver. This is indepen-
dently supported by studies that show proteasome inhibi-
tors fail to enhance transgene expression following AAV8 
gene transfer [44, 45], although this has been suggested 
to be dependent on the size of the transgene [45].
No indication of toxicity from vector infusions 
in hemophilia B dogs
Of the three dogs injected, only one animal O19 displayed 
a mild rise in alanine transaminase (ALT) levels, slightly 
above the upper limit of the reference range provided by 
the clinical diagnostic laboratory Antech Inc. This eleva-
tion was noted prior to vector infusion at baseline and 
remained in the normal range up to 3  weeks following 
vector infusion. ALT levels again rose above normal range 
on day 97 and remained so until the end of the study. Dog 
O58, which received a threefold higher vector dose com-
pared to O19, maintained normal ALT levels suggesting 
that this mild elevation in ALT was unrelated to the vec-
tor. All animals had a mild reduction in platelet counts 
during follow-up. Perioperative reductions in plate-
let counts are probably due to fluid and normal canine 
plasma administration as well as some consumption at 
surgical wound sites. Even though some of the values are 
below the lower end of the reference range, they are not 
at a level that would be associated with clinical bleeding. 
Dogs O19 and O58 had mild elevations in hematocrit and 
hemoglobin levels throughout follow-up and the cause of 
these mild elevations is not known. Overall the dogs had 
no clinical concerns related to these small elevations, ate 
well and maintained body weight throughout the study.
Limitations of pre-clinical models in general and of the 
mouse model in particular
One of the frustrations with pre-clinical studies on vector 
development has been that the different animal models 
may yield substantially differing results on the efficacy of 
Fig. 4 Administration of AAV2-LiC-ApoE-haat-cF9 to a hemophilia B dog leads to only minimal correction of coagulation. a C57BL/6 mice were 
intravenously injected with 2 × 1010 vg of the AAV2-(Y-F)-M3-ApoE-hAAT-cF9 vector or 1 × 1010 vg of the AAV2-LiC-ApoE-hAAT-cF9 and levels 
of circulating cFIX protein were measured by ELISA at 4 weeks post gene delivery. b, c A hemophilia B dog, Bruce, was peripherally injected with 
6 × 1011 vg/kg of an AAV2-LiC-ApoE-hAAT-cF9 vector and followed over time for changes in b WBCT and c % cFIX activity. Fold difference between 
groups in a are listed above and the amount of “*” and p value is included as reported by an unpaired T test
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hepatic gene transfer. While AAV2 transduction has been 
fairly consistent between species, other serotypes vary con-
siderably. For example, AAV8 transduces murine liver 1–2 
logs more efficiently than AAV2 (Fig. 5a) [40]. In the canine 
model, AAV2, 8, and 9 yield similar results, while these 
serotypes perform quite distinctly in mouse liver [5, 33, 47]. 
Interestingly, AAV2 and 8 also directed similar FIX levels 
in humans [11, 12]. It is therefore possible that limitations 
exist in non-murine species that are not yet understood. 
In the study presented here, FIX levels achieved in hemo-
philia B dogs, when adjusted for vector dose, were slightly 
less for AAV2-(Y-F)-M3 (Fig.  2) compared to historical 
data on AAV2 (Fig. 5b) [30, 31]. However, when consider-
ing that the vector constructs are not entirely identical, 
were purified with different methods, and were not titered 
side-by-side, and that the animals are an outbred strain, we 
conclude that AAV2 and AAV2-(Y-F)-M3 capsids perform 
similarly in dogs. This contrasts with the 0.5- to 1-log dif-
ference in expression seen in mouse models [15, 16].
Both dogs that were treated with AAV2-(Y-F)-M3 were 
at the approximately the same age and weight at the time 
of vector injection (Table 2) but received a threefold dif-
ferent vector dose per kg. During the first 2  months 
after gene transfer, no clear difference in cFIX expres-
sion was obvious. However, the animal treated with the 
lower vector dose (O19), had a hematoma and required 
a second round of infusion with normal canine plasma 
at  ~2  weeks after gene transfer (it takes 8–17  days for 
aPTT (activity) and 14–27  days for WBTC to return to 
baseline following transfusion of cFIX protein [46]). Dur-
ing the third month after gene transfer, WBCT and cFIX 
activity measurements suggest an ~twofold higher levels 
of expression in the animal receiving a threefold higher 
dose (O58). Given biological variability, this outcome is 
within the expected range, while more animals would be 
required to determine an exact dose response.
In contrast to the introduction of point mutations to 
eliminate specific L, Y, T, and S residues, AAV2-LiC capsid 
had been obtained through a molecular evolution strat-
egy, involving generation of a combinatorial capsid library 
and repeated in  vivo selection in murine liver. Liver-
derived FIX expression after peripheral vein injection of 
AAV2-LiC into different strains of mice is as high as that 
obtained with AAV8 (Fig. 5a) [20], resulting in induction 
of robust immune tolerance to FIX in hemophilia B mice 
(Fig. 3a–c). However, AAV2-LiC performed poorly in the 
canine model (Fig.  4), with substantially lower efficacy 
than for example previously reported for AAV8 (Fig. 5b) 
[33, 48]. We therefore conclude that selection for optimal 
variants in mouse liver likely results in mouse-specific 
efficacy that does not translate to other species.
Implications for future studies and translation
In order to better predict performance of hepatic gene 
transfer with a particular capsid in human patients, two 
strategies have been adapted: studies in non-human pri-
mates and experiments in immune deficient mice whose 
livers have been partially reconstituted with human 
hepatocytes [4, 5, 35, 49, 50]. In the humanized mouse 
model, we found that different serotypes had highly dis-
tinct transduction efficiencies of human hepatocytes, 
which were often opposite to their relative performance 
in mouse hepatocytes [5]. An advantage of this model is 
that human and mouse cell transduction can be directly 
compared in the same animal. Of the different capsids 
tested, engineered AAV3 (containing S663V and T492V 
mutations) outperformed AAV5, 8, and 9 in human 
hepatocytes [5]. Others who used this model to select 
for capsids from a “shuffled” library, representing recom-
bined sequences derived from multiple serotypes, also 
found a capsid primarily consisting of AAV3 sequences 
to most optimally transduce human hepatocytes [49].
Conclusions
While only clinical trials can ultimately determine suit-
ability for human gene therapy, it has become clear that 
results in mouse liver are often not predictive of efficacy 
in other species or in human liver, so that alternative 
models need to be used to test rationally designed capsid 
variants and to select for capsids via directed molecular 
evolution. New data emerging from ongoing clinical tri-
als evaluating different AAV serotypes will aid in inform-
ing which animal model provides the best predictive 
value for human liver gene transfer efficacy.
Fig. 5 Summary of wild-type and mutant AAV capsids relative liver 
gene transfer efficiency in a mice and b dogs. Fold difference is 
reported on a log scale. 0.5 log is equivalent to ~threefold difference
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Additional files
Additional file 1: Table S1. Clinical chemistry panel for hemophilia B 
dog O19. Baseline values obtained prior to vector. Pre refers to blood 
collected on the day of vector administrations and post and onward refer 
to time points after vector delivery. Low values are colored blue, values 
within normal ranges are black, and values above normal ranges are red.
Additional file 2: Table S2. Clinical chemistry panel for hemophilia 
B dog O58. Baseline values obtained prior to vector. Day 0 refers to the 
day of vector administration. Low values are colored blue, values within 
normal ranges are black, and values above normal ranges are red.
Additional file 3: Figure S1. No evidence of bethesda inhibitors in 
either AAV2-(Y-F)-M3 or AAV2-LiC vector treated hemophilia B dogs. 
Plasma from selected time points was measured for Bethesda inhibitor 
titer and are reported as Bethesda units per mL (BU/mL). Data for each 
animal and the respective vector, delivery route, and dose are represented 
by a different color (O19-blue, O58-red, Bruce-Green). AAV2-M3 is an 
abbreviation of AAV2-(Y-F)-M3. PV portal vein, IV intravenous.
Additional file 4: Table S3. Clinical chemistry panel for hemophilia B 
dog Bruce. Baseline values obtained prior to vector. Day 0 refers to the 
day of vector administration. Low values are colored blue, values within 
normal ranges are black, and values above normal ranges are red.
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